-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vididencel in Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vididencel in Ovarian Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vididencel in Ovarian Cancer Drug Details: vididencel is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PMX-205 in Parkinson’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PMX-205 in Parkinson's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PMX-205 in Parkinson's Disease Drug Details: PMX-205 (TDI0116) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Emactuzumab in Brenner Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Emactuzumab in Brenner Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Emactuzumab in Brenner Tumor Drug Details: Emactuzumab (RG-7155, RO5509554) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Plogosertib in Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Plogosertib in Leukemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Plogosertib in Leukemia Drug Details: Plogosertib is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Zanubrutinib in Refractory Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Zanubrutinib in Refractory Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Zanubrutinib in Refractory Chronic Lymphocytic Leukemia (CLL) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Emrusolmin in Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Emrusolmin in Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Emrusolmin in Multiple System...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Emrusolmin in Parkinson’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Emrusolmin in Parkinson's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Emrusolmin in Parkinson's Disease Drug Details: Emrusolmin (TEV-56286) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CD19/CD22 CAR-T in B-Cell Non-Hodgkin Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CD19/CD22 CAR-T in B-Cell Non-Hodgkin Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CD19/CD22 CAR-T in B-Cell Non-Hodgkin Lymphoma Drug Details: Gene...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – STAR-0602 in Epithelial Ovarian Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. STAR-0602 in Epithelial Ovarian Cancer Drug Details: STAR-0602 is under development for the treatment of...
-
Product Insights
Dystonia – Drugs In Development, 2023
Global Markets Direct’s, ‘Dystonia - Drugs In Development, 2023’, provides an overview of the Dystonia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Dystonia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...